Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide

Rassol, Nishte ; Ytterbrink, Charlotte ; Pettersson, Daniella ; Al-Awar, Amin ; Bakr, Hana ; Gram, Magnus LU orcid ; Spetz, Johan and Forssell-Aronsson, Eva (2025) In Radiation Protection Dosimetry 201(13-14). p.995-1005
Abstract

Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding... (More)

Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60 MBq 177Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6-10 weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Radiation Protection Dosimetry
volume
201
issue
13-14
pages
11 pages
publisher
Oxford University Press
external identifiers
  • pmid:40875274
  • scopus:105014624194
ISSN
0144-8420
DOI
10.1093/rpd/ncaf090
language
English
LU publication?
yes
id
dddb24f2-8a68-4c08-a1fd-39602943dcfa
date added to LUP
2025-10-16 13:04:43
date last changed
2025-10-17 04:03:12
@article{dddb24f2-8a68-4c08-a1fd-39602943dcfa,
  abstract     = {{<p>Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as <sup>177</sup>Lu-octreotate and <sup>177</sup>Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from <sup>177</sup>Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with <sup>177</sup>Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60 MBq <sup>177</sup>Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6-10 weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.</p>}},
  author       = {{Rassol, Nishte and Ytterbrink, Charlotte and Pettersson, Daniella and Al-Awar, Amin and Bakr, Hana and Gram, Magnus and Spetz, Johan and Forssell-Aronsson, Eva}},
  issn         = {{0144-8420}},
  language     = {{eng}},
  number       = {{13-14}},
  pages        = {{995--1005}},
  publisher    = {{Oxford University Press}},
  series       = {{Radiation Protection Dosimetry}},
  title        = {{Evaluation of coadministration schedules of rA1M for kidney protection after administration of <sup>177</sup>Lu-octreotide}},
  url          = {{http://dx.doi.org/10.1093/rpd/ncaf090}},
  doi          = {{10.1093/rpd/ncaf090}},
  volume       = {{201}},
  year         = {{2025}},
}